Biomarker discovery to clinical utility
Progression from biomarker discovery to development of complex protein signatures for clinical use, involves challenging stages like verification and diverse cohort validation. Traditionally, technology switches hinder progress. Olink’s Proximity Extension Assay (PEA) bridges this gap, offering quality and versatility from discovery to clinical signature development, illustrated by multiple success stories.
Webinar
Discover how scientists from Octave Bioscience developed a custom panel for monitoring multiple sclerosis disease activity using the Olink platform.
The clinical impact of biomarker discoveries
Explore pivotal studies demonstrating how biomarker research transitions into clinical advancements, underlining the journey from discovery to utility.
One platform.
Endless possibilities.
Explore up to 5,400 proteins with high specificity, transparent data, and the flexibility to answer any research question. Meet the next-generation proteomics platform trusted by small lab teams and leading pharma companies.
Olink Explore HT
Measure 5,400+ proteins with proven specificity to gain an understanding of disease at the protein level.
Proteins
5,400+ With proven specificity
Sample
2 µL Plasma, serum & more
Olink Target 96
Target specific disease areas or key biological processes with multiplex immunoassay panels.
Proteins
1,100+ On 15 targeted panels
Sample
1 µL Plasma, serum & more
Olink Target 48
Extensively validated and carefully selected biomarkers for a comprehensive view of cytokine signaling and inflammatory processes.
Proteins
89 On 2 panels
Sample
1 µL Plasma, serum & more
Olink Focus
Custom designed panels that transition you from biomarker discovery to clinical utility of protein signatures.
Proteins
Up to 21 Pre-validated assays
Sample
1 µL Plasma, serum & more